These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11504469)

  • 1. Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bacheler LT
    Drug Resist Updat; 1999 Feb; 2(1):56-67. PubMed ID: 11504469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
    Kilby JM; Saag MS
    Infect Agents Dis; 1994 Dec; 3(6):313-23. PubMed ID: 7534192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The search for potent, small molecule NNRTIs: A review.
    Prajapati DG; Ramajayam R; Yadav MR; Giridhar R
    Bioorg Med Chem; 2009 Aug; 17(16):5744-62. PubMed ID: 19632850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.
    Sweeney ZK; Klumpp K
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):458-70. PubMed ID: 18600563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
    Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
    ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
    Domaoal RA; Demeter LM
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
    De Clercq E
    Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase.
    Götte M; Wainberg MA
    Drug Resist Updat; 2000 Feb; 3(1):30-38. PubMed ID: 11498363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of NNRTIs on HIV reverse transcriptase dimerization.
    Tachedjian G; Goff SP
    Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
    D'Cruz OJ; Uckun FM
    J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Das K; Lewi PJ; Hughes SH; Arnold E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):209-31. PubMed ID: 15572156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
    SPREAD programme
    AIDS; 2008 Mar; 22(5):625-35. PubMed ID: 18317004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.